http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 09:01:41 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Arcutis+promotes+Mas+Matsuda+to+chief+legal+officer/26116235.html <p>Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) announced the promotion of Mas Matsuda from senior vice president and general counsel to executive vice president, chief legal officer, and corporate secretary.</p> <p>Matsuda will continue leading the company's legal, compliance, and governance strategy while supporting commercialization of the ZORYVE portfolio and protecting intellectual property. The Westlake Village, California-based biopharmaceutical company focuses on immuno-dermatology treatments.</p> <p>Frank Watanabe, president and chief executive officer, said Matsuda has been instrumental in strengthening the company's legal and compliance foundation while supporting ZORYVE development and growth.</p> <p>Matsuda joined Arcutis in January 2022 as general counsel and corporate secretary. During his tenure, he guided http://www.streetinsider.com/Management+Changes/Arcutis+promotes+Mas+Matsuda+to+chief+legal+officer/26116235.html Thu, 05 Mar 2026 09:01:41 -0500 ARQT http://www.streetinsider.com/Press+Releases/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html <p>WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=L5f9robQNgLEQc5-uzYWjzvwITmV4l5ys3nxRZkH4BUuO6L87YzLBnveGmnQbZoEE97sbkUS-S2kTbAEGGf-7CVBQHUWHIv8Qw90cN1_A0Y=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE^® (roflumilast) portfolio, and protection of the Company’s intellectual property, as well as any corporate transactions.</p> <p>“I am thrilled to http://www.streetinsider.com/Press+Releases/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html Thu, 05 Mar 2026 09:00:00 -0500 ARQT ARQT http://www.streetinsider.com/Press+Releases/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html <p>WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=L5f9robQNgLEQc5-uzYWjzvwITmV4l5ys3nxRZkH4BUuO6L87YzLBnveGmnQbZoEE97sbkUS-S2kTbAEGGf-7CVBQHUWHIv8Qw90cN1_A0Y=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE^® (roflumilast) portfolio, and protection of the Company’s intellectual property, as well as any corporate transactions.</p> <p>“I am thrilled to http://www.streetinsider.com/Press+Releases/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html Thu, 05 Mar 2026 09:00:00 -0500 ARQT ARQT http://www.streetinsider.com/Globe+Newswire/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html <p>WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=L5f9robQNgLEQc5-uzYWjzvwITmV4l5ys3nxRZkH4BUuO6L87YzLBnveGmnQbZoEE97sbkUS-S2kTbAEGGf-7CVBQHUWHIv8Qw90cN1_A0Y=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE^® (roflumilast) portfolio, and protection of the Company’s intellectual property, as well as any corporate transactions.</p> <p>“I am thrilled to http://www.streetinsider.com/Globe+Newswire/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html Thu, 05 Mar 2026 09:00:00 -0500 ARQT ARQT http://www.streetinsider.com/Globe+Newswire/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html <p>WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=L5f9robQNgLEQc5-uzYWjzvwITmV4l5ys3nxRZkH4BUuO6L87YzLBnveGmnQbZoEE97sbkUS-S2kTbAEGGf-7CVBQHUWHIv8Qw90cN1_A0Y=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotion of Mas Matsuda, JD, currently senior vice president and general counsel, to executive vice president, chief legal officer, and corporate secretary. Mr. Matsuda will continue to lead the Company’s legal, compliance, and governance strategy in support of the continued growth of the Company, commercialization of the ZORYVE^® (roflumilast) portfolio, and protection of the Company’s intellectual property, as well as any corporate transactions.</p> <p>“I am thrilled to http://www.streetinsider.com/Globe+Newswire/Arcutis+Announces+Promotion+of+Mas+Matsuda+to+Executive+Vice+President+and+Chief+Legal+Officer+to+Support+Next+Phase+of+Growth/26116156.html Thu, 05 Mar 2026 09:00:00 -0500 ARQT ARQT http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Leonard+Keith+R/26111422.html si-local-file:///var/storage/secattach/20260304/26111422.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Leonard+Keith+R/26111422.html Wed, 04 Mar 2026 16:18:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Leonard+Keith+R/26111422.html si-local-file:///var/storage/secattach/20260304/26111422.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Leonard+Keith+R/26111422.html Wed, 04 Mar 2026 16:18:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Welgus+Howard+G./26111384.html si-local-file:///var/storage/secattach/20260304/26111384.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Welgus+Howard+G./26111384.html Wed, 04 Mar 2026 16:16:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Welgus+Howard+G./26111384.html si-local-file:///var/storage/secattach/20260304/26111384.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Mar+02++Filed+by%3A+Welgus+Howard+G./26111384.html Wed, 04 Mar 2026 16:16:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Watanabe+Todd/26105457.html si-local-file:///var/storage/secattach/20260303/26105457.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Watanabe+Todd/26105457.html Tue, 03 Mar 2026 20:43:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Watanabe+Todd/26105457.html si-local-file:///var/storage/secattach/20260303/26105457.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Watanabe+Todd/26105457.html Tue, 03 Mar 2026 20:43:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Edwards+Larry+Todd/26105459.html si-local-file:///var/storage/secattach/20260303/26105459.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Edwards+Larry+Todd/26105459.html Tue, 03 Mar 2026 20:43:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Edwards+Larry+Todd/26105459.html si-local-file:///var/storage/secattach/20260303/26105459.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Edwards+Larry+Todd/26105459.html Tue, 03 Mar 2026 20:43:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Aug+18++Filed+by%3A+Burnett+Patrick/26105454.html si-local-file:///var/storage/secattach/20260303/26105454.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Aug+18++Filed+by%3A+Burnett+Patrick/26105454.html Tue, 03 Mar 2026 20:42:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Aug+18++Filed+by%3A+Burnett+Patrick/26105454.html si-local-file:///var/storage/secattach/20260303/26105454.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Aug+18++Filed+by%3A+Burnett+Patrick/26105454.html Tue, 03 Mar 2026 20:42:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Vairavan+Latha/26105455.html si-local-file:///var/storage/secattach/20260303/26105455.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Vairavan+Latha/26105455.html Tue, 03 Mar 2026 20:42:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Vairavan+Latha/26105455.html si-local-file:///var/storage/secattach/20260303/26105455.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Vairavan+Latha/26105455.html Tue, 03 Mar 2026 20:42:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Matsuda+Masaru/26105456.html si-local-file:///var/storage/secattach/20260303/26105456.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Matsuda+Masaru/26105456.html Tue, 03 Mar 2026 20:42:00 -0500 ARQT O.46864665 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Matsuda+Masaru/26105456.html si-local-file:///var/storage/secattach/20260303/26105456.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Arcutis+Biotherapeutics%2C++For%3A+Feb+27++Filed+by%3A+Matsuda+Masaru/26105456.html Tue, 03 Mar 2026 20:42:00 -0500 ARQT O.46864665 http://www.streetinsider.com/FDA/Arcutis+starts+phase+1+study+of+ARQ-234+for+atopic+dermatitis/26096736.html <p>Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) has enrolled the first participant in a Phase 1a/1b study evaluating ARQ-234, an investigational treatment for atopic dermatitis. The double-blind, randomized, placebo-controlled study will assess the safety and tolerability of the subcutaneous injection in healthy volunteers and adults with moderate to severe atopic dermatitis.</p> <p>The study, designated ARQ-234-131, will enroll approximately 125 participants aged 18 to 65 years across three sequential parts. Part A involves single-ascending doses in healthy participants and adults with atopic dermatitis over 16 weeks. Part B includes multiple-ascending doses in atopic dermatitis patients over 30 weeks. Part C comprises a proof-of-concept expansion http://www.streetinsider.com/FDA/Arcutis+starts+phase+1+study+of+ARQ-234+for+atopic+dermatitis/26096736.html Tue, 03 Mar 2026 08:00:29 -0500 ARQT http://www.streetinsider.com/Press+Releases/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html <ul type="disc"><li style="margin-bottom:10pt;">Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis</li><li style="margin-bottom:10pt;">ARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance</li></ul> <p>WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=irUW6hbc1GNtaDLOqas5MoF33B9fWN_G5gkZaIfvuSn4c5sgk6o4e9hJCjNqoSaIWs2mSphtVarBn410M1Bom7kURy2potEt4U-0z7pz8zM=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the safety and tolerability of ARQ-234. The http://www.streetinsider.com/Press+Releases/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html Tue, 03 Mar 2026 08:00:00 -0500 ARQT ARQT http://www.streetinsider.com/Press+Releases/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html <ul type="disc"><li style="margin-bottom:10pt;">Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis</li><li style="margin-bottom:10pt;">ARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance</li></ul> <p>WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=irUW6hbc1GNtaDLOqas5MoF33B9fWN_G5gkZaIfvuSn4c5sgk6o4e9hJCjNqoSaIWs2mSphtVarBn410M1Bom7kURy2potEt4U-0z7pz8zM=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the safety and tolerability of ARQ-234. The http://www.streetinsider.com/Press+Releases/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html Tue, 03 Mar 2026 08:00:00 -0500 ARQT ARQT http://www.streetinsider.com/Globe+Newswire/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html <ul type="disc"><li style="margin-bottom:10pt;">Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis</li><li style="margin-bottom:10pt;">ARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance</li></ul> <p>WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=irUW6hbc1GNtaDLOqas5MoF33B9fWN_G5gkZaIfvuSn4c5sgk6o4e9hJCjNqoSaIWs2mSphtVarBn410M1Bom7kURy2potEt4U-0z7pz8zM=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the safety and tolerability of ARQ-234. The http://www.streetinsider.com/Globe+Newswire/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html Tue, 03 Mar 2026 08:00:00 -0500 ARQT ARQT http://www.streetinsider.com/Globe+Newswire/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html <ul type="disc"><li style="margin-bottom:10pt;">Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitis</li><li style="margin-bottom:10pt;">ARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an immune-regulatory checkpoint involved in maintaining immune balance</li></ul> <p>WESTLAKE VILLAGE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=irUW6hbc1GNtaDLOqas5MoF33B9fWN_G5gkZaIfvuSn4c5sgk6o4e9hJCjNqoSaIWs2mSphtVarBn410M1Bom7kURy2potEt4U-0z7pz8zM=" rel="nofollow" target="_blank"><u>Arcutis Biotherapeutics, Inc.</u></a> (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the first participant has been enrolled in a Phase 1a/1b, double-blind, randomized, placebo-controlled study, ARQ-234-131, evaluating the safety and tolerability of ARQ-234. The http://www.streetinsider.com/Globe+Newswire/Arcutis+Begins+Enrolling+Phase+1a1b+Study+Evaluating+ARQ-234%2C+a+CD200R+Agonist%2C+in+Healthy+Volunteers+and+Adults+With+Atopic+Dermatitis/26096685.html Tue, 03 Mar 2026 08:00:00 -0500 ARQT ARQT http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcutis+Biotherapeutics%2C+++++++++++++++Filed+by%3A+Matsuda+Masaru/26094479.html si-local-file:///var/storage/secattach/20260302/26094479.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Arcutis+Biotherapeutics%2C+++++++++++++++Filed+by%3A+Matsuda+Masaru/26094479.html Mon, 02 Mar 2026 18:49:00 -0500 ARQT O.46864665